确定近端股骨转移瘤切除或内固定(PERFORM)随机对照试验临床均势区间的调查
本研究通过调查确定PERFORM随机对照试验的临床均势区间,该试验将比较近端股骨转移瘤的切除加假体重建与内固定。调查面向骨科肿瘤医生,评估驱动手术决策的患者和骨病变特征。结果显示,可接受两种手术方式的患者包括预期寿命至少6个月、骨丢失25%至75%、围手术期并发症风险低至中等。93%的受访者表示有兴趣参与PERFORM试验。
要点
- PERFORM试验的初步均势区间为骨丢失25%至75%、手术并发症风险低至中等、预期寿命至少6个月的患者。
- 调查对象为北美、南美、欧洲、亚洲和非洲的76名外科医生,应答率为70%。
- 93%的受访者表示有兴趣参与PERFORM试验。
核心结论
- PERFORM试验的初步均势区间包括骨丢失25%至75%、手术并发症风险低至中等、预期寿命至少6个月的患者。
研究设计与样本
- 一项调查,开发、试点后分发给自我声明对PERFORM试验感兴趣的利益相关者,目标人群为骨科肿瘤医生。
- 在牵头学术机构获得伦理豁免,数据收集于REDCap调查数据库。
主要发现
- 来自北美、南美、欧洲、亚洲和非洲的76名外科医生完成了应答。
- 自我声明感兴趣利益相关者的应答率为70%,并从更广泛的国际受众中收集了额外应答。
- 应答表明,切除加假体重建或内固定均可接受的研究人群包括:预期寿命至少6个月、骨丢失不超过75%且不低于25%、围手术期并发症风险低至中等。
- 93%的受访者表示有兴趣参与PERFORM试验。
关键数值与推荐
- 可接受两种手术方式的患者特征包括预期寿命至少6个月、骨丢失25%至75%、围手术期并发症风险低至中等。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to establish a zone of clinical equipoise for the Proximal FEmur Resection or Internal Fixation fOR Metastases (PERFORM) randomized controlled trial, which will compare resection and endoprosthetic reconstruction to internal fixation for skeletal metastases of the proximal femur. METHODS: A survey was developed, piloted, and distributed to self-declared interested stakeholders in the PERFORM trial. The survey targeted orthopedic oncologists and was designed to assess patient and bone lesion characteristics that drive surgical decision-making in the treatment of skeletal metastases in the proximal femur. An Ethics Waiver was obtained at the lead academic institution and data was collected in the REDCap survey database. RESULTS: Responses were complete from 76 surgeons across North America, South America, Europe, Asia, and Africa. Response rate from self-declared interested stakeholders was 70%, with additional responses collected from a broader international audience. Responses indicate that a study population for which either resection and endoprosthetic reconstruction or internal fixation are acceptable options include (1) life expectancy at least 6 months, (2) bone loss of no more than 75% and no less than 25%, and (3) minimal to moderate risk for perioperative complications. Ninety-three percent of respondents indicated that they would be interested in participating in the PERFORM trial. CONCLUSION: A preliminary zone of equipoise for the PERFORM trial includes patients with 25-75% bone loss, low to moderate risk of operative complications, and life expectancy of at least 6 months. Further stakeholder discussions have finalized the PERFORM trial protocol prior to study initiation.
引用
- Fogel J, Ng VY, Schubert T, et al. A survey to determine the zone of equipoise for the Proximal FEmur Resection or Internal Fixation fOR Metastases (PERFORM) randomized controlled trial. Trials. 2024. PMID: 39533439. doi:10.1186/s13063-024-08590-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。